James N. Topper - 15 Sep 2025 Form 4 Insider Report for NewAmsterdam Pharma Co N.V. (NAMS)

Reporting relationship: Director
Issuer ticker: NAMS
Reported as of: 15 Sep 2025
Net transaction value: +$15,639
SEC form: 4
Accepted by SEC: 17 Sep 2025, 17:22:34 UTC
Prior SEC filing: 10 Sep 2025
Next SEC filing: 21 May 2026
Source filing: View source filing
Reporting owner signature: /s/ Steve R. Bailey, Attorney-in-Fact For James N. Topper

Key filing fact

James N. Topper filed Form 4 for NewAmsterdam Pharma Co N.V. (NAMS) on 17 Sep 2025.

Key facts

This page summarizes James N. Topper's Form 4 filing for NewAmsterdam Pharma Co N.V. (NAMS).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 17 Sep 2025, 17:22.

Change

Previous filing in this sequence was filed on 10 Sep 2025.
Current net transaction value: +$15,639.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001341382 Primary reporting owner

Topper James N

Relationship: Director
Address: 1001 PAGE MILL RD, BUILDING 4, SUITE B, PALO ALTO
Signature: /s/ Steve R. Bailey, Attorney-in-Fact For James N. Topper
Signature date: 17 Sep 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

NAMS transaction

Ordinary Shares

Purchase

Transaction value: $15,639
Shares: +660
Change %: +0.02%
Price: $23.70
Shares after: 3,028,524
Date: 15 Sep 2025
Ownership: By Frazier Life Sciences X, L.P.
Footnotes: F1, F2

NAMS holding

Ordinary Shares

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 3,801,000
Date: 15 Sep 2025
Ownership: By Frazier Lifesciences Sponsor LLC
Footnotes: F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $23.46 to $23.75. inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (3) to this Form 4.

Footnote F2

The shares are held directly by Frazier Life Sciences X, L.P. FHMLS X, L.P. is the general partner of Frazier Life Sciences X, L.P. and FHMLS X, L.L.C. is the general partner of FHMLS X, L.P. The Reporting Person is one of two managing members of FHMLS X, L.L.C. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.

Footnote F3

The shares are held directly by Frazier Lifesciences Sponsor LLC. The sole member of Frazier Lifesciences Sponsor LLC is Frazier Life Sciences X, L.P. FHMLS X, L.P. is the general partner of Frazier Life Sciences X, L.P. and FHMLS X, L.L.C. is the general partner of FHMLS X, L.P. The Reporting Person is one of two managing members of FHMLS X, L.L.C. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.